title: Risks and outcome of fungal infection in neutropenic children with hematologic diseases.
abstract: In this retrospective study, we report the results of antifungal treatments (AFTs) in febrile neutropenic episodes in patients with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and aplastic anemia (AA) in our center. From January 2004 to December 2005, a total of 52 patients and 221 febrile neutropenic episodes were evaluated. AFT was started in 96 (43%) of the 221 episodes. Amphotericin B and fluconazole were used in 44 (46%) and 52 (54%) febrile neutropenic episodes, respectively. Microbiologically or histopathologically evident fungal infections were detected in 35 of 96 febrile neutropenic episodes. The mortality rate due to fungal infection was higher in patients with AA (7/8 patients) and AML (7/12 patients) than in ALL patients (1/32). Mortality for the whole group was 28%. When the mortality rate was compared between the two treatment groups (amphotericin B vs fluconazole), mortality was significantly higher in patients receiving amphotericin B [n = 14 (93%) and n = 1 (7%), respectively].
authors.affiliation: Unit of Hematology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.
authors.forename: Selin
authors.initials: S
authors.lastname: Aytaç
authors.forename: Inci
authors.initials: I
authors.lastname: Yildirim
authors.forename: Mehmet
authors.initials: M
authors.lastname: Ceyhan
authors.forename: Mualla
authors.initials: M
authors.lastname: Cetin
authors.forename: Murat
authors.initials: M
authors.lastname: Tuncer
authors.forename: Ateş
authors.initials: A
authors.lastname: Kara
authors.forename: A Bülent
authors.initials: AB
authors.lastname: Cengiz
authors.forename: Gülten
authors.initials: G
authors.lastname: Seçmeer
authors.forename: Sevgi
authors.initials: S
authors.lastname: Yetgin
mesh_terms: D000293:Adolescent; D000666:Amphotericin B / Q000627:therapeutic use; D000741:Anemia, Aplastic / Q000150:complications* / Q000401:mortality; D000935:Antifungal Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000401:mortality; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D009503:Neutropenia / Q000150:complications* / Q000401:mortality; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000401:mortality; D012189:Retrospective Studies; D012306:Risk; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B; D015725:Fluconazole